Relationship between Thrombotic Events and Peripheral Neutrophil-to-lymphocyte Ratio in Patients with Newly Diagnosed Essential Thrombocythemia.
10.19746/j.cnki.issn.1009-2137.2019.02.036
- Author:
Dian ZHOU
1
;
Hai CHENG
1
;
Wei CHEN
1
;
Zhen-Yu LI
1
;
Kai-Lin XU
2
Author Information
1. Institute of Hematology, Xuzhou Medical University The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China.Department of Hematology.The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China.
2. Institute of Hematology, Xuzhou Medical University The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China.Department of Hematology.The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China.E-mail: lihmd@163.com.
- Publication Type:Journal Article
- MeSH:
Humans;
Lymphocyte Count;
Lymphocytes;
Neutrophils;
Prognosis;
Retrospective Studies;
Thrombocythemia, Essential;
Thrombosis
- From:
Journal of Experimental Hematology
2019;27(2):534-538
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the role of neutrophil-to-lymphocyte ratio（NLR) in patients with newly diagnosed essential thrombocythemia（ET) and its relationship with thrombotic events.
METHODS:The clinical and follow-up data of 150 ET patients were retrospectively analyzed. The risk factors of thrombotic events and role of NLR by statistical methods.
RESULTS:Age (P<0.01) and JAK2V617F mutation (P<0.01) were the independent risk factors for thrombotic events at diagnosis; WBC count (P<0.05), NLR (P<0.01), age (P<0.05) and thrombosis history at diagnosis (P<0.05) were independent risk factors for future thrombotic events. The ROC curve showed that NLR for prediction of future thrombotic events was suprior to other risk factors. The Kaplan-Meier analysis showed that the progress-free survival time in thrombotic events patients with higher NLR (median survival 22.3 months, 95% CI:17.8-26.8) was significantly shorter than that of patients with lower NLR (median survival 55.5 months, 95% CI:53.4-57.5) . After follow-up 60 months, the thrombosis progress-free survival in lower NLR patients reached 97.4%, while that in the patients with higher NLR was rate 46.7%.
CONCLUSION:NLR at diagnosis is a better predictive parameter for future thrombotic events than other clinical parameters in ET patients, but without corralations with thrombosis at diagnosis.
